Kioga Inc.
A vaccine against weight gain.
The University of Colorado Connection
Kioga is discovering and commercializing new dietary ingredients to "vaccinate" consumers against stress and metabolic disorders by targeting brain and body inflammation. Kioga is based on work arising from the laboratories of Ìý(ÎÞÂëÊÓÆµ Integrative Physiology) and Ìý(ÎÞÂëÊÓÆµ Ecology and Evolutionary Biology). , cofounder of eat meatiâ„¢ (Meati Inc.), joined Kioga as CEO through the Venture Partners Embark Deep Tech Startup Creator in 2024.
Funding Status and Investment Opportunities
- Industry Applications: Biotech​, Food and Agriculture, Health and Wellness​
- Funding Stage: Seed
- Contact for Investment Inquiries: hello@kioga.bio
In the News
- ÎÞÂëÊÓÆµ hosts showcases highlighting breakthrough innovations and investment-ready ventures (2025)
- Destination Startup announces startups across the region to present at annual showcase (2026)
- (2025)
- OEDIT announces grants to ÎÞÂëÊÓÆµ and CU Denver startups and researchers (2025)
- ÎÞÂëÊÓÆµ startups selected for Innosphere's 2025 Life Sciences Incubator (2025)
- ÎÞÂëÊÓÆµ hosts showcases highlighting breakthrough innovations and investment-ready ventures (2025)
- A vaccine against weight gain? It’s on the horizon (2023)
Venture Partners Programs​
- Destination Startup (2026)
- Embark Deep Tech Startup Creator (2024)
- Intellectual Property Management (2023)
Technology Development Funding

U.S. National Institutes of Health
ÌýÌý ÌýThis page was last updated on Feb. 5, 2026. Please contact vpnews@colorado.edu for corrections or updates
The Insider Investor eNewsletter
The InsiderÌýisÌýVenture Partners at ÎÞÂëÊÓÆµ's monthly newsletter featuring theÌýlatest headlines, news, events, opportunities and emerging innovations from the university. We have several editions for our audiences.
Questions ÎÞÂëÊÓÆµ Investment Opportunities?
Media Inquiries
For marketing inquiries and news tips, contact Daniel Leonard,Ìýsenior marketing and communications specialist for Venture Partners at ÎÞÂëÊÓÆµ.
For media inquiries, please visit .
